Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, from Mayo Clinic opens a conversation around CDK4/6 inhibitor prescription for patients diagnosed with early breast cancer.
Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
Results from the monarchE trial are analyzed by Hope Rugo, MD, and Joyce O'Shaughnessy, MD.
Dr. Dempsey discusses key results from the NATALEE and MonarchE trials.
A panel of experts discuss sequencing considerations with CDK4/6.
A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.
Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.
Dr. Rugo details her management strategy in regards to GI toxicities.
A medical expert navigates toxicity management in patients being treated with ribociclib.
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
3
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
4
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
5